Erxian Soup Together Naphthalene Small Beauty One Clinical Study Of The Treatment Of Female Liver-kidney Menopausal Osteoarthritis (early)

Objectives:To compare the clinical effect of the therapy combining Erxian Decoction with Nabumetone with that of the therapy applying Nabumetone only for female menopausal osteoarthritis patients of liver and kidney yin deficiency syndrome, explore the impacts of Eexian Decoction to E2(main indicator) and ALP,BMD (secodary indicators), and offer objective basis for correlation of the indicators above..Materials and methods:Clinical altogether collected73cases, of which fall off in3,70cases were randomly divided into2groups,35cases in treatment group and35cases in control group. The control group was given non-steroidal anti-inflammatory drugs Nabumetone capsule, two times each day, one pill each time for8weeks. The treatment group was given Erxian Decoction and Nabumetone capsule, with Erxian Decoction (decocted in water), one dose each day, two times each day for8weeks, and Nabumetone capsule, two times each day, one pill each time for8weeks. Statistical method:Applying SPSS13.0software for statistical analysis. Measurement data with the mean+SD (x±s), were compared between groups using independent samples t test, within group comparisons using the paired t test; count data by using x2test; rank data using the Kruskal-Wallis test. P<0.05indicates statistically significant difference.Result:①Clinical efficacy:Total effective rate of treatment group was94.29%, and that of control group was74.29%. The difference was statistically significant (P<0.05), indicating that the efficacy of the treatment group was superior to that of the control group.②TCM syndromes:Total effective rate of treatment group was91.43%, while that of the control group was68.75%, the difference was statistically significant (P<0.05), indicating that the efficacy of the treatment group was superior to that of the control group.③TCM symptoms:Five symptoms including arthralgia, joint dysfunction, irritability, palpitation and insomnia, fever and sweating were remarkably relieved. Differences between the two groups were statistically significant (P<0.05), indicating that the efficacy of the treatment group was superior to that of the control group.④The main indicator E2and the secondary indicator BMD remains normal level after the treatment (P>0.05) while another secondary indicator ALP rises (P<0.05)Conclusion:The therapy combining Erxian Decoction with Nabumctone can relieve clinical symptoms of menopausal osteoarthritis patients in liver and kidney yin deficiency syndrome, especially TCM symptoms, thus is worth to be widely applied in clinic.